Resiquimod

Neoplasm

Eikon TherapeuticsSmall moleculePhase 2Active

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 81/ 100

Competitive context

889 Active assets in the Neoplasm cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
Granulocyte Colony-Stimulating Factor Lenograstim Sanofi	Phase 4	BB
Dexmedetomidine Medical College of Wisconsin	Phase 4	BB
Lidocaine Medical College of Wisconsin	Phase 4	BB
Relatlimab Bristol-Myers Squibb	Phase 2	BB

View all 50 →

Same molecule, other indications

Resiquimod is also rated in:

melanomaActive

B

Indicative · Phase 2

62 / 100

anaplastic astrocytomaDormant

B

Indicative · Phase 2

57 / 100

anaplastic oligoastrocytomaDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.